These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21450126)

  • 21. Reflections on the evolution of health technology assessment in Europe.
    Sorenson C; Chalkidou K
    Health Econ Policy Law; 2012 Jan; 7(1):25-45. PubMed ID: 22221927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
    Denburg AE; Giacomini M; Ungar WJ; Abelson J
    Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanding the scientific basis of health technology assessment: a research agenda for the next decade.
    Battista RN
    Int J Technol Assess Health Care; 2006; 22(3):275-80; discussion 280-2. PubMed ID: 16984053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health technology assessment: principles, methods and current status.
    Giovagnoni A; Bartolucci L; Manna A; Morbiducci J; Ascoli G
    Radiol Med; 2009 Aug; 114(5):673-91. PubMed ID: 19367465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe.
    Löblová O
    Health Econ Policy Law; 2016 Jul; 11(3):253-73. PubMed ID: 26670267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-Based Decision Making 3: Health Technology Assessment.
    O'Reilly D; Audas R; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2021; 2249():429-454. PubMed ID: 33871857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized medicine--a tailored health care system: challenges and opportunities.
    Louca S
    Croat Med J; 2012 Jun; 53(3):211-3. PubMed ID: 22661133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HTA of medical devices: Challenges and ideas for the future from a European perspective.
    Fuchs S; Olberg B; Panteli D; Perleth M; Busse R
    Health Policy; 2017 Mar; 121(3):215-229. PubMed ID: 27751533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Innovation in health care: the role of HTA in the introduction of new technologies].
    Bührlen B
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):703-8. PubMed ID: 21147431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
    Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
    BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health technology assessment and private payers's coverage of personalized medicine.
    Trosman JR; Van Bebber SL; Phillips KA
    Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
    Allen N; Pichler F; Wang T; Patel S; Salek S
    Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies.
    Gaultney JG; Bouvy JC; Chapman RH; Upton AJ; Kowal S; Bokemeyer C; Solà-Morales O; Wolf J; Briggs AH
    Appl Health Econ Health Policy; 2021 Sep; 19(5):625-634. PubMed ID: 34028672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Joint project of the International Network of Agencies for Health Technology Assessment--Part 2: Managing the diffusion of positron emission tomography with health technology assessment.
    Adams EJ; Almazán C; Mørland B; Bradbury I; King R; Rheinberger P
    Int J Technol Assess Health Care; 2006; 22(2):149-54. PubMed ID: 16571189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientific Development of HTA-A Proposal by the Health Technology Assessment International Scientific Development and Capacity Building Committee.
    van der Wilt GJ; Rüther A; Trowman R
    Int J Technol Assess Health Care; 2019; 35(4):263-265. PubMed ID: 31355736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status.
    Rosselli D; Quirland-Lazo C; Csanádi M; Ruiz de Castilla EM; González NC; Valdés J; Abicalaffe C; Garzón W; Leon G; Kaló Z
    Value Health Reg Issues; 2017 Dec; 14():20-27. PubMed ID: 29254537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The current status and problems confronted in delivering precision medicine in Japan and Europe.
    Bando H
    Curr Probl Cancer; 2017; 41(3):166-175. PubMed ID: 28391973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.